- Home
- FLC vs GBIO Comparison
FLC vs GBIO Comparison
Compare FLC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- GBIO
- Stock Information
- Founded
- FLC 2003
- GBIO 2016
- Country
- FLC United States
- GBIO United States
- Employees
- FLC N/A
- GBIO N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- GBIO Health Care
- Exchange
- FLC Nasdaq
- GBIO Nasdaq
- Market Cap
- FLC 180.6M
- GBIO 64.8M
- IPO Year
- FLC N/A
- GBIO 2020
- Fundamental
- Price
- FLC $16.59
- GBIO $0.88
- Analyst Decision
- FLC
- GBIO Strong Buy
- Analyst Count
- FLC 0
- GBIO 2
- Target Price
- FLC N/A
- GBIO $6.50
- AVG Volume (30 Days)
- FLC 37.8K
- GBIO 581.0K
- Earning Date
- FLC 01-01-0001
- GBIO 03-05-2025
- Dividend Yield
- FLC 6.64%
- GBIO N/A
- EPS Growth
- FLC N/A
- GBIO N/A
- EPS
- FLC N/A
- GBIO N/A
- Revenue
- FLC N/A
- GBIO $18,582,000.00
- Revenue This Year
- FLC N/A
- GBIO $212.74
- Revenue Next Year
- FLC N/A
- GBIO N/A
- P/E Ratio
- FLC N/A
- GBIO N/A
- Revenue Growth
- FLC N/A
- GBIO 514.08
- 52 Week Low
- FLC $12.62
- GBIO $0.75
- 52 Week High
- FLC $15.45
- GBIO $4.65
- Technical
- Relative Strength Index (RSI)
- FLC 44.20
- GBIO 28.66
- Support Level
- FLC $16.46
- GBIO $0.85
- Resistance Level
- FLC $16.89
- GBIO $1.01
- Average True Range (ATR)
- FLC 0.22
- GBIO 0.12
- MACD
- FLC -0.01
- GBIO 0.00
- Stochastic Oscillator
- FLC 36.00
- GBIO 7.50
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.